Cafepharma Today

June 5 2025 - GLP-1 drugs may be linked to elevated risk of serious eye disease, study finds
GLP-1 drugs may be linked to elevated risk of serious eye disease, study finds
Bispecific cancer drugs, data caveats and funding alarms: 3 takeaways from ASCO
FDA’s Elsa AI is here, and the industry has questions
Merck gains U.S. patent office support in Keytruda dispute
*please scroll down for all the latest news *

Make it like cafepharma, but for different industries. Learn more about CompanyUnderground

Check open job listings in your area
Click here to stay updated on CP happenings

learn about pharmaceutical fraud
learn about the False Claims Act
learn about clinical lab fraud

Current News

submit a press release

[video]Should Merck Copy Pfizer and Join the "Spinoff Club"?
Motley Fool
Saturday, September 28, 2013 - 11:05am
tags:
Merck
A Promising Future For Anthera's Blisibimod
Seeking Alpha
Saturday, September 28, 2013 - 11:04am
tags:
lupus, blisibimod, Anthera
AstraZeneca Vaccine Update
Yahoo/Zacks
Saturday, September 28, 2013 - 11:02am
tags:
vaccines, flu vaccines, AstraZeneca
Bristol-Myers: Interesting Investing Opportunity With Onglyza
Seeking Alpha
Saturday, September 28, 2013 - 11:00am
tags:
type 2 diabetes, Onglyza, diabetes, Bristol-Myers Squibb, AstraZeneca
Nektar's Pain Drug Disappoints
Yahoo/Zacks
Saturday, September 28, 2013 - 10:59am
tags:
pain management, NKTR-181, Nektar
Bristol’s Yervoy Adds Up to 10 Years of Life for Cancer Patients
Bloomberg
Saturday, September 28, 2013 - 10:57am
tags:
Yervoy, Bristol-Myers Squibb
Synta Announces Presentation of Ganetespib Results at the 2013 European Cancer Congress
Yahoo/BusinessWire
Saturday, September 28, 2013 - 10:55am
tags:
Synta Pharmaceuticals, lung cancer, ganetespib
Arno Therapeutics to Present Data Validating Target Biomarker at European Cancer Congress 2013
Yahoo/Globe Newswire
Saturday, September 28, 2013 - 10:52am
tags:
onapristone, breast cancer, biomarkers, Arno Therapeutics
ImmunoGen, Inc. Announces Results from Kadcyla® Phase III Trial, TH3RESA, Being Presented Today at the European Cancer Congress
Yahoo/BusinessWire
Saturday, September 28, 2013 - 10:46am
tags:
Roche, Kadcyla, Immunogen, breast cancer
Exelixis Announces Presentation of Updated Phase 1b Data for Cobimetinib (GDC-0973/XL518) in Combination with Vemurafenib at ECC 2013
Yahoo/BusinessWire
Saturday, September 28, 2013 - 10:44am
tags:
metastatic melanoma, melanoma, Exelixis, Cobimetinib
ARIAD Presents Updated Phase 1/2 Data on AP26113 in Patients with Non-Small Cell Lung Cancer
Yahoo/BusinessWire
Saturday, September 28, 2013 - 10:42am
tags:
non-small cell lung cancer, Ariad Pharmaceuticals, AP26113
Phase 3 Trial Comparing Vectibix® (Panitumumab) to Erbitux® (Cetuximab) Meets Primary Endpoint Of Non-Inferiority Of Overall Survival
Yahoo/PR NewsWire
Saturday, September 28, 2013 - 10:41am
tags:
Vectibix, colorectal cancer, Amgen
For Arena, Belviq Refills Are Becoming Key
Seeking Alpha
Saturday, September 28, 2013 - 10:39am
tags:
Belviq, Arena Pharmaceuticals
The Rosen Law Firm Announces Investigation of Shareholder Securities Claims Against Prosensa Holding NV – RNA
Yahoo/BusinessWire
Saturday, September 28, 2013 - 10:38am
tags:
Prosensa, lawsuits
Does a Lack of Interest Tell You This Biotech Has Limited Upside?
Motley Fool
Saturday, September 28, 2013 - 10:36am
tags:
Clovis Oncology
Jazz Pharmaceuticals Stares At Generic Threat, Thrives
investors.com
Saturday, September 28, 2013 - 10:34am
tags:
Jazz Pharmaceuticals, generics
Actos jury says Takeda failed at safety warnings, but judge tosses $1.7M verdict
Fierce Pharma
Friday, September 27, 2013 - 11:55am
tags:
Actos, Takeda, bladder cancer, diabetes
FDA officials take to social media outlet Twitter to spread a message about its new mobile medical application rules: regulation will be passive
Mass Device
Friday, September 27, 2013 - 11:52am
tags:
devices, FDA, twitter, social media, mHealth, mobile medical apps
ArQule up on hope for lung cancer drug revival
Reuters
Friday, September 27, 2013 - 11:51am
tags:
Arqule, tivantinib, Daiichi Sankyo, lung cancer
Inotek snags $21M for PhII glaucoma drops
Fierce Biotech
Friday, September 27, 2013 - 11:48am
tags:
Inotek, glaucoma

Pages

Latest CP Wire Articles

Hermes Intelligence Launches to Redefine Pharma Data Solutions [sponsored]
The Evolution of Medical Sales: What’s Changing in 2025?
FDA Scraps Key Vaccine Meetings—What It Means for Manufacturers
FDA approves Danziten, the first nilotinib treatment for Ph+ CML with no mealtime restrictions
Daily U.S. Flu Cases Expected to Nearly Double from Last Year by Late November, Predicts Novel Mathematical Forecasting Tool
PharmaBlock Receives 2024 ACS CMO Excellence in Green Chemistry Award, Marking a Second Consecutive Year of Recognition
Leading Clinical Research Network Centricity Research Acquires North Carolina-based Lucas Research
First-of-Its-Kind Alzheimer’s Disease Simulation Paves Way for Personalized Treatment: Penn State, Duke University Study
Centricity Research Appoints New CEO, CFO to Support Next Phase of Growth
Sermo Barometer Examines Influencers’ Impact on Patient Perceptions of Weight Loss Medications & Preventative Care Technologies

Latest Pharmagather Articles

Not One of Your Easy Crystals
In the Pipeline
The Continuing Crisis, Part XV: The Horrendous Trump Budget
In the Pipeline
Taurine Revisited
In the Pipeline
A New Route to Asthma Treatment - Through the Liver, of All Places
In the Pipeline
One Drug's Supply Chain, In Detail
In the Pipeline
A Reaction to Alzheimer's Fraud
In the Pipeline
Whoa Now: Cautionary Tales from Materials Science
In the Pipeline
Inside a Scientific Paper Mill
In the Pipeline
Autoimmune Disease, Transformed?
In the Pipeline

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.